肾脏磷酸盐丢失可预测多囊肾病不良结局
在604例常染色体显性多囊肾病(ADPKD)患者中,59%存在肾脏磷酸盐丢失(TmP/GFR<0.8 mmol/L)。校正PTH、FGF-23和eGFR后,TmP/GFR每降低0.1 mmol/L,eGFR下降加快0.2 mL/min/1.73 m2/年(95%CI 0.01;0.3),复合肾脏结局风险HR为1.09(95%CI 1.01;1.18)。
要点
- ADPKD患者中肾脏磷酸盐丢失常见,占59%。
- TmP/GFR降低与更快的eGFR下降及复合肾脏结局风险升高独立相关。
- 磷酸盐丢失可能与早期近端小管功能障碍及PTH抑制不足有关。
核心结论
- ADPKD患者中磷酸盐丢失普遍存在,且与更快的疾病进展相关。
研究设计与样本
- 多中心前瞻性观察性队列(DIPAK研究),纳入荷兰四家大学医学中心的604例ADPKD患者。
主要发现
- 队列年龄48±12岁,男性39%,eGFR 63±28 mL/min/1.73 m2,59%存在磷酸盐丢失。
- 男性(系数-0.2,95%CI -0.2;-0.1)、eGFR(0.002,95%CI 0.001;0.004)、FGF-23(0.1,95%CI 0.03;0.2)、PTH(-0.2,95%CI -0.3;-0.06)及copeptin(-0.08,95%CI -0.1;-0.08)与TmP/GFR相关。
- 校正PTH、FGF-23和eGFR后,TmP/GFR每降低0.1 mmol/L,eGFR下降加快0.2 mL/min/1.73 m2/年(95%CI 0.01;0.3)。
- 校正PTH、FGF-23和eGFR后,TmP/GFR每降低0.1 mmol/L,复合肾脏结局HR为1.09(95%CI 1.01;1.18)。
关键数值与推荐
- TmP/GFR<0.8 mmol/L定义为肾脏磷酸盐丢失。
- 复合肾脏结局定义为eGFR下降≥30%、肾衰竭或肾脏替代治疗。
临床怎么用
- 在ADPKD患者中,TmP/GFR降低(每降低0.1 mmol/L)与eGFR下降加快及复合肾脏结局风险升高独立相关,校正PTH、FGF-23和eGFR后仍显著。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with autosomal dominant polycystic kidney disease (ADPKD) have disproportionately high levels of fibroblast growth factor 23 (FGF-23) for their chronic kidney disease stage, however only a subgroup develops kidney phosphate wasting. We assessed factors associated with phosphate wasting and hypothesize that it identifies patients with more severe disease and predicts disease progression. METHODS: We included 604 patients with ADPKD from a multicenter prospective observational cohort (DIPAK; Developing Intervention Strategies to Halt Progression of Autosomal Dominant Polycystic Kidney Disease) in four university medical centers in the Netherlands. We measured parathyroid hormone (PTH) and total plasma FGF-23 levels, and calculated the ratio of tubular maximum reabsorption rate of phosphate to glomerular filtration rate (TmP/GFR) with <0.8 mmol/L defined as kidney phosphate wasting. We analysed the association of TmP/GFR with estimated GFR (eGFR) decline over time and the risk for a composite kidney outcome (≥30% eGFR decline, kidney failure or kidney replacement therapy). RESULTS: In our cohort (age 48 ± 12 years, 39% male, eGFR 63 ± 28 mL/min/1.73 m2), 59% of patients had phosphate wasting. Male sex [coefficient -0.2, 95% confidence interval (CI) -0.2; -0.1], eGFR (0.002, 95% CI 0.001; 0.004), FGF-23 (0.1, 95% CI 0.03; 0.2), PTH (-0.2, 95% CI -0.3; -0.06) and copeptin (-0.08, 95% CI -0.1; -0.08) were associated with TmP/GFR. Corrected for PTH, FGF-23 and eGFR, every 0.1 mmol/L decrease in TmP/GFR was associated with a greater eGFR decline of 0.2 mL/min/1.73 m2/year (95% CI 0.01; 0.3) and an increased hazard ratio of 1.09 (95% CI 1.01; 1.18) of the composite kidney outcome. CONCLUSION: Our study shows that in patients with ADPKD, phosphate wasting is prevalent and associated with more rapid disease progression. Phosphate wasting may be a consequence of early proximal tubular dysfunction and insufficient suppression of PTH.
引用
- Xue L, Geurts F, Meijer E, et al. Kidney phosphate wasting predicts poor outcome in polycystic kidney disease. Nephrol Dial Transplant. 2024. PMID: 37985930. doi:10.1093/ndt/gfad247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。